Amplia announces A$25m Placement and Launches A$2.5m SPP
Filed with ASX · · 5 pages · English
Summary by 6ix AI
The placement was well-received by both existing and new institutional investors, with firm commitments already secured for shortfall shares under the share purchase plan. Funds raised will help accelerate the company's clinical studies and support future trials, with expectations for top-line data from the ACCENT trial soon.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Amplia Therapeutics Ltd. on 6ix
In the deck
Story so far
Earlier from Amplia Therapeutics
- Second Complete Response in ACCENT Pancreatic Cancer Trial
- Pathological complete response recorded in patient from ACCENT cancer trial
- Pathological Complete Response in Pancreatic Cancer Trial
- Preliminary Final Report and Annual Report YE 31 March 2025
- ACCENT Trial Achieves Superiority over Chemotherapy Alone
Later from Amplia Therapeutics
- Capital Raising Presentation
- Positive ACCENT Trial Topline Data Released
- Amplia Share Purchase Plan Raises $2.65 Million
- First patient dosed in new pancreatic cancer trial
- Amplia Receives R&D Tax Rebate Totalling $3.77 Million
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics